Drug Profile

SYNB 1618

Alternative Names: SYN PKU; SYNB-1618

Latest Information Update: 29 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Synlogic
Class Probiotics
Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Phenylketonuria
New Molecular Entity No

Highest Development Phases

Phase II Phenylketonuria
Discontinued Hyperoxaluria; Maple syrup urine disease

Most Recent Events

20 Mar 2023 Efficacy and adverse events data from a phase Synpheny-1 study in Phenylketonuria released by Synlogic
06 Jan 2023 Phase II developement in Phenylketonuria is still ongoing in USA (PO)
18 Oct 2022 Efficacy and adverse events data from a phase Synpheny-1 study in Phenylketonuria released by Synlogic

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com